专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010019206A1 ANTIFUNGAL AGENTS 审中-公开
标题翻译：反真菌药
公开(公告)号：WO2010019206A1
公开(公告)日：2010-02-18
申请号：PCT/US2009/004569
申请日：2009-08-10
申请人： MERCK SHARP & DOHME CORP. , SCYNEXIS, INC. , GREENLEE, Mark, L. , WILKENING, Robert , APGAR, James , SPERBECK, Donald , WILDONGER, Kenneth, James , MENG, Dongfang , PARKER, Dann, L., Jr. , MAMAI, Ahmed
发明人： GREENLEE, Mark, L. , WILKENING, Robert , APGAR, James , SPERBECK, Donald , WILDONGER, Kenneth, James , MENG, Dongfang , PARKER, Dann, L., Jr. , MAMAI, Ahmed
IPC分类号： A01N43/64 , A61K31/21 , A61K31/41
CPC分类号： A61K31/21 , A61K31/41 , C07D405/04
摘要： Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
摘要翻译：本文公开了enfumafungin的新型衍生物以及“其药学上可接受的盐，水合物和前药”。还公开了包含这种化合物的组合物，制备这些化合物的方法和使用这种化合物作为（1,3）-β-D-葡聚糖合酶的抗真菌剂和/或抑制剂的方法。所公开的化合物，其药学上可接受的盐，水合物和前药，以及包含这些化合物，盐，水合物和前药的组合物可用于治疗和/或预防真菌感染和相关疾病和病症。

2. 发明申请

WO2010019204A1 ANTIFUNGAL AGENTS 审中-公开
标题翻译：反真菌药
公开(公告)号：WO2010019204A1
公开(公告)日：2010-02-18
申请号：PCT/US2009/004560
申请日：2009-08-07
申请人： MERCK SHARP & DOHME CORP. , SCYNEXIS, INC. , GREENLEE, Mark, L. , WILKENING, Robert , APGAR, James , SPERBECK, Donald , WILDONGER, Kenneth, James , MENG, Dongfang , PARKER, Dann, L. , PACOFSKY, Gregory, James , HEASLEY, Brian, Haid , MAMAI, Ahmed , NELSON, Kingsley
发明人： GREENLEE, Mark, L. , WILKENING, Robert , APGAR, James , SPERBECK, Donald , WILDONGER, Kenneth, James , MENG, Dongfang , PARKER, Dann, L. , PACOFSKY, Gregory, James , HEASLEY, Brian, Haid , MAMAI, Ahmed , NELSON, Kingsley
IPC分类号： A01N43/64 , A61K31/21 , A61K31/41
CPC分类号： A61K31/343 , A01N43/653 , A61K31/21 , A61K31/41 , C07D493/08 , C07D519/00
摘要： Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs,,as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
摘要翻译：本文公开了enfumafungin的新型衍生物及其药学上可接受的盐，水合物和前药。还公开了包含这种化合物的组合物，制备这些化合物的方法和使用这种化合物作为抗真菌剂和/或（1,3）-β-D-葡聚糖合酶抑制剂的方法。所公开的化合物，其药学上可接受的盐，水合物和前药以及包含这些化合物，盐，水合物和前药的组合物可用于治疗和/或预防真菌感染和相关疾病和病症。

3. 发明申请

WO2012064569A1 IMIDAZOLE DERIVATIVES 审中-公开
标题翻译：咪唑衍生物
公开(公告)号：WO2012064569A1
公开(公告)日：2012-05-18
申请号：PCT/US2011/059033
申请日：2011-11-03
申请人： MERCK SHARP & DOHME CORP. , SCHERING CORPORATION , SPERBECK, Donald, M. , DEVITA, Robert, J. , BALKOVEC, James, M. , GREENLEE, Mark, L. , WU, Zhicai , YU, Yang , VACHAL, Petr , ZHOU, Gang , WU, Heping , KUANG, Rongze , TING, Pauline , ASLANIAN, Robert
发明人： SPERBECK, Donald, M. , DEVITA, Robert, J. , BALKOVEC, James, M. , GREENLEE, Mark, L. , WU, Zhicai , YU, Yang , VACHAL, Petr , ZHOU, Gang , WU, Heping , KUANG, Rongze , TING, Pauline , ASLANIAN, Robert
IPC分类号： A01N43/40
CPC分类号： C07D401/14 , C07D401/04
摘要： Described herein are compounds of formula (I), formula la or formula lb The compounds of formula I, formula la or formula lb act as DGATl inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
摘要翻译：本文描述的是式（I），式Ia或式Ib的化合物。式I，式Ia或式Ib的化合物作为DGAT1抑制剂，可用于预防，治疗或作为高脂血症，糖尿病和肥胖。

4. 发明申请

WO2006062876A3 ESTROGEN RECEPTOR MODULATORS 审中-公开
标题翻译：雌激素受体调节剂
公开(公告)号：WO2006062876A3
公开(公告)日：2006-09-14
申请号：PCT/US2005043859
申请日：2005-12-05
申请人： MERCK & CO INC , GREENLEE MARK L , MENG DONGFANG , SPERBECK DONALD M , WILDONGER KENNETH J
发明人： GREENLEE MARK L , MENG DONGFANG , SPERBECK DONALD M , WILDONGER KENNETH J
IPC分类号： A61K31/41 , C07D403/12
CPC分类号： C07D249/16
摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
摘要翻译：本发明涉及其化合物及其衍生物，其合成及其作为雌激素受体调节剂的用途。本发明的化合物是雌激素受体的配体，因此可用于治疗或预防与雌激素功能相关的各种病症，包括：骨丢失，骨折，骨质疏松症，转移性骨病，佩吉特氏病，牙周病，软骨变性，子宫内膜异位症，子宫肌瘤病，热潮红症，低密度脂蛋白胆固醇水平升高，心血管疾病，认知功能障碍，年龄相关性轻度认知障碍，脑退行性疾病，再狭窄，男子乳腺发育不良，血管平滑肌细胞增生，肥胖，失禁，炎症，炎性肠病，肠易激综合征，性功能障碍，高血压，视网膜变性和癌症，特别是乳腺，子宫和前列腺。

5. 发明申请

WO2006062876A2 ESTROGEN RECEPTOR MODULATORS 审中-公开
标题翻译：雌激素受体调节剂
公开(公告)号：WO2006062876A2
公开(公告)日：2006-06-15
申请号：PCT/US2005/043859
申请日：2005-12-05
申请人： MERCK & CO., INC. , GREENLEE, Mark, L. , MENG, Dongfang , SPERBECK, Donald, M. , WILDONGER, Kenneth, J.
发明人： GREENLEE, Mark, L. , MENG, Dongfang , SPERBECK, Donald, M. , WILDONGER, Kenneth, J.
IPC分类号： C07D403/02
CPC分类号： C07D249/16
摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget’s disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
摘要翻译：本发明涉及化合物及其衍生物，它们的合成，以及它们作为雌激素受体调节剂的用途。本发明的化合物是雌激素受体的配体，因此可用于治疗或预防与雌激素功能有关的多种病症，包括：骨丢失，骨折，骨质疏松症，转移性骨疾病，佩吉特氏病，牙周病，软骨退化，子宫内膜异位，子宫肌瘤疾病，潮热，LDL胆固醇水平升高，心血管疾病，认知功能障碍，年龄相关的轻度认知障碍，脑退行性疾病，再狭窄，男子女性型乳房，血管平滑肌细胞增殖，肥胖，失禁，炎症，炎性肠病，肠易激综合征，性功能障碍，高血压，视网膜变性和癌症，特别是乳房，子宫和前列腺。

6. 发明申请

WO2015051725A1 ANTIDIABETIC TRICYCLIC COMPOUNDS 审中-公开
标题翻译：抗菌三环化合物
公开(公告)号：WO2015051725A1
公开(公告)日：2015-04-16
申请号：PCT/CN2014/087857
申请日：2014-09-30
申请人： MERCK SHARP & DOHME CORP. , BIFTU, Tesfaye , BIJU, Purakkatle , COLLETTI, Steven L. , CUI, Mingxiang , HAGMANN, William K. , HU, Bin , JOSIEN, Hubert , KAR, Nam Fung , NAIR, Anilkumar , NARGUND, Ravi , SPERBECK, Donald M. , ZHU, Chen
发明人： BIFTU, Tesfaye , BIJU, Purakkatle , COLLETTI, Steven L. , CUI, Mingxiang , HAGMANN, William K. , HU, Bin , JOSIEN, Hubert , KAR, Nam Fung , NAIR, Anilkumar , NARGUND, Ravi , SPERBECK, Donald M. , ZHU, Chen
IPC分类号： C07D221/16 , C07D401/12 , C07D401/14 , A61K31/444 , A61K31/438 , A61P3/10
CPC分类号： C07D221/16 , A61K31/435 , A61K31/444 , A61K45/06 , C07D401/12 , C07D405/12
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译：结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗，预防和抑制G蛋白偶联受体受体40.本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖症和脂质疾病，例如混合或糖尿病性血脂异常，高脂血症，高胆固醇血症和高甘油三酯血症。

7. 发明申请

WO2012164071A1 IMIDAZOLE DERIVATIVES 审中-公开
标题翻译：咪唑衍生物
公开(公告)号：WO2012164071A1
公开(公告)日：2012-12-06
申请号：PCT/EP2012/060381
申请日：2012-06-01
申请人： INTERVET INTERNATIONAL B.V. , DE VITA, Robert, J. , HONG, QingMei , LAI, Zhong , DYKSTRA, Kevin, D. , YU, Yang , LIU, Jian , SPERBECK, Donald , JIAN, Tianying , GUIADEEN, Deodial , XU-QIANG YANG, Ginger , WU, Zhicai , HE, Shuwen , TING, Pauline, C. , ASLANIAN, Robert , KUETHE, Jeffrey, T. , BALKOVEC, James, M. , KUANG, Rongze , ZHOU, Gang , WU, Heping
发明人： DE VITA, Robert, J. , HONG, QingMei , LAI, Zhong , DYKSTRA, Kevin, D. , YU, Yang , LIU, Jian , SPERBECK, Donald , JIAN, Tianying , GUIADEEN, Deodial , XU-QIANG YANG, Ginger , WU, Zhicai , HE, Shuwen , TING, Pauline, C. , ASLANIAN, Robert , KUETHE, Jeffrey, T. , BALKOVEC, James, M. , KUANG, Rongze , ZHOU, Gang , WU, Heping
IPC分类号： C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61K31/4188 , A61P3/00
CPC分类号： C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D493/04
摘要： Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
摘要翻译：本文描述的是式（I）的化合物。式I化合物作为DGAT1抑制剂，可用于预防，治疗或作为高脂血症，糖尿病和肥胖症的补救剂。

8. 发明申请

WO2012096813A1 IMIDAZOLE DERIVATIVES 审中-公开
标题翻译：咪唑衍生物
公开(公告)号：WO2012096813A1
公开(公告)日：2012-07-19
申请号：PCT/US2012/020191
申请日：2012-01-04
申请人： MERCK SHARP & DOHME CORP. , LIU, Jian , BALKOVEC, James, M. , KRIKORIAN, Arto, D. , GUIADEEN, Deodial , YANG, Ginger , JIAN, Tianying , WU, Zhicai , YU, Yang , NARGUND, Ravi, P. , VACHAL, Petr , DEVITA, Robert, J. , HE, Shuwen , LAI, Zhong , BLEVIS-BAL, Radhika, M. , CERNAK, Timothy, A. , SPERBECK, Donald, M. , HONG, Qingmei
发明人： LIU, Jian , BALKOVEC, James, M. , KRIKORIAN, Arto, D. , GUIADEEN, Deodial , YANG, Ginger , JIAN, Tianying , WU, Zhicai , YU, Yang , NARGUND, Ravi, P. , VACHAL, Petr , DEVITA, Robert, J. , HE, Shuwen , LAI, Zhong , BLEVIS-BAL, Radhika, M. , CERNAK, Timothy, A. , SPERBECK, Donald, M. , HONG, Qingmei
IPC分类号： C07D227/06
CPC分类号： C07D227/06
摘要： Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
摘要翻译：本文描述的是式I化合物。式I化合物作为DGAT1抑制剂，可用于预防，治疗或作为高脂血症，糖尿病和肥胖症的补救剂。

9. 发明申请

WO2012009217A1 SPIROCYCLIC COMPOUNDS 审中-公开
标题翻译：螺环化合物
公开(公告)号：WO2012009217A1
公开(公告)日：2012-01-19
申请号：PCT/US2011/043330
申请日：2011-07-08
申请人： MERCK SHARP & DOHME CORP. , CERNAK, Timothy, A. , BALKOVEC, James, M. , NARGUND, Ravi, P. , REITER, Maud , SPERBECK, Donald, M. , DYKSTRA, Kevin, D. , YU, Yang , DREHER, Spencer , MALONEY, Kevin, M. , WU, Zhicai , DEVITA, Robert, J. , VERRAS, Andreas
发明人： CERNAK, Timothy, A. , BALKOVEC, James, M. , NARGUND, Ravi, P. , REITER, Maud , SPERBECK, Donald, M. , DYKSTRA, Kevin, D. , YU, Yang , DREHER, Spencer , MALONEY, Kevin, M. , WU, Zhicai , DEVITA, Robert, J. , VERRAS, Andreas
IPC分类号： A01N43/40 , A61K31/44 , A61K31/435
CPC分类号： C07D491/10 , C07D401/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D491/20 , C07D498/10 , C07D519/00
摘要： Described herein are compounds of formula (I) (Formula (I)). The compounds of formula (I) act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
摘要翻译：本文描述的是式（I）（式（I））的化合物。式（I）化合物作为DGAT1抑制剂，可用于预防，治疗或作为高脂血症，糖尿病和肥胖症的补救剂。

10. 发明申请

WO2003082841A1 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS 审中-公开
标题翻译：作为PTPASE 1B抑制剂的5-取代的1,1-DIOXO-1,2,5！噻唑烷-3-酮衍生物
公开(公告)号：WO2003082841A1
公开(公告)日：2003-10-09
申请号：PCT/EP2003/003466
申请日：2003-04-02
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , COPPOLA, Gary, Mark , DAVIES, John, William , JEWELL, Charles, Francis, Jr. , LI, Yu-Chin , WAREING, James, Richard , SPERBECK, Donald, Mark , STAMS, Travis, Mathew , TOPIOL, Sidney, Wolf , VLATTAS, Isidoros
发明人： COPPOLA, Gary, Mark , DAVIES, John, William , JEWELL, Charles, Francis, Jr. , LI, Yu-Chin , WAREING, James, Richard , SPERBECK, Donald, Mark , STAMS, Travis, Mathew , TOPIOL, Sidney, Wolf , VLATTAS, Isidoros
IPC分类号： C07D285/10
CPC分类号： C07D285/10 , C07D417/06 , C07D417/10 , C07K5/06078
摘要： Compounds of the formula (I) provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula (I) inhibit PTP-1 B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.
摘要翻译：式（I）的化合物提供作为PTP酶抑制剂的药理学试剂，特别是抑制PTP-1B和TC PTP的式（I）化合物，因此可用于治疗与PTPase活性相关的病症。本发明的化合物也可用于抑制具有磷酸酪氨酸结合区的其它酶，例如SH2结构域。因此，式（I）化合物可用于预防或治疗与大，小血管的肥胖，葡萄糖不耐受，糖尿病，高血压和缺血性疾病相关的胰岛素抵抗。本发明的化合物也可用于治疗，预防或控制伴随2型糖尿病的多种病症，包括高脂血症，高甘油三酯血症，动脉粥样硬化，血管再狭窄，肠易激综合征，胰腺炎，脂肪细胞瘤和癌。作为脂肪肉瘤，血脂异常和其他指示胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗或预防癌症，骨质疏松症，神经变性和感染性疾病以及涉及炎症和免疫系统的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式